Department of Neurosurgery, Qilu Hospital of Shandong University, 107 Wenhua West Road, Jinan 250012, China.
J Clin Neurosci. 2009 Dec;16(12):1595-8. doi: 10.1016/j.jocn.2009.02.036. Epub 2009 Sep 29.
To study the clinical characteristics, treatment and prognosis of patients with glioblastoma multiforme (GBM) in China, we retrospectively analyzed 205 Chinese patients with histologically proven GBM. A univariate analysis of prognosis factors for survival time was performed and significant factors were tested in a multivariate analysis using the Cox regression method. Median overall survival time was 12.0 months (95% confidence interval [CI] 11.0-13.1 months). Survival rates after diagnosis were 82% at 6 months, 52% at 12 months, 27% at 18 months and 17% at 24 months. Age, preoperative Karnofsky's performance status score and tumour location were independent preoperative predictors of prognosis and among the treatment methods of GBM, radiotherapy was the strongest predictor of prognosis followed by radical surgery and chemotherapy. The median survival time post diagnosis for Chinese patients is comparable to the 11.0-15.9 month range observed in western patients. The data suggest a lack of ethnic differences in GBM prognosis of Chinese and western patients.
为了研究中国人胶质母细胞瘤（GBM）患者的临床特征、治疗方法和预后，我们回顾性分析了 205 例经组织学证实的 GBM 中国患者。对生存时间的预后因素进行了单因素分析，并使用 Cox 回归方法对有意义的因素进行了多因素分析。中位总生存时间为 12.0 个月（95%置信区间 11.0-13.1 个月）。诊断后 6 个月的生存率为 82%，12 个月为 52%，18 个月为 27%，24 个月为 17%。年龄、术前卡诺夫斯基表现状态评分和肿瘤位置是独立的术前预后预测因素，在 GBM 的治疗方法中，放疗是最强的预后预测因素，其次是根治性手术和化疗。中国患者的中位诊断后生存时间与西方患者观察到的 11.0-15.9 个月范围相当。数据表明，中国和西方 GBM 患者的预后无种族差异。
